axatilimab   Click here for help

GtoPdb Ligand ID: 13497

Synonyms: Ab969 [US9908939] | axatilimab-csfr | INCA034176 | Niktimvo® | SNDX-6352 | UCB-6352
Approved drug
axatilimab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Axatilimab (SNDX-6352, formerly UCB-6352) is a humanized anti-CSF-1R antibody. It was initially developed as an alternative therapeutic modality for the treatment of chronic graft-versus-host disease (GvHD) [2]. Axatilimab targets macrophage-mediated inflammation and fibrosis that cause organ damage in GvHD, by blocking CSF-1R activation by either of its ligands (CSF-1 and IL-34).
Peptide sequences from the axatilimab INN entry align with sequences that are claimed in a UCB Biopharma patent originally filed in 2014 [1].
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2024))
International Nonproprietary Names Click here for help
INN number INN
10953 axatilimab
Synonyms Click here for help
Ab969 [US9908939] | axatilimab-csfr | INCA034176 | Niktimvo® | SNDX-6352 | UCB-6352
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 942
Other databases
GtoPdb PubChem SID 500839907
Search PubMed clinical trials axatilimab
Search PubMed titles axatilimab
Search PubMed titles/abstracts axatilimab